var data={"title":"Doripenem: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Doripenem: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/336670?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=doripenem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Doripenem: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10805264\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Doribax [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432406\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Carbapenem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432441\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A switch to appropriate oral antimicrobial therapy may be considered after 3 days of parenteral therapy and demonstrated clinical improvement.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intra-abdominal infection, complicated:</b> IV: 500 mg every 8 hours for 5 to 14 days. <b>Note:</b> IDSA guidelines recommend treatment duration of 4 to 7 days (provided source controlled). Not recommended for mild to moderate, community-acquired intra-abdominal infections (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection, complicated (including pyelonephritis):</b> IV: 500 mg every 8 hours for 10 days (14 days with concurrent bacteremia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection (complicated) or pyelonephritis:</b> IV: 500 mg every 8 hours for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous catheter-related bloodstream infection (off-label use):</b> IV: 500 mg every 8 hours for 7 to 14 days (IDSA, 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432442\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432443\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Renal function estimated using the Cockcroft-Gault formula:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 30 to 50 mL/minute: 250 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 11 to 29 mL/minute: 250 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Dialyzable (~52% of dose removed during 4-hour session in ESRD patients): 250 mg every 24 hours; if treating infections caused by <i>Pseudomonas aeruginosa</i>, administer 500 mg every 12 hours on day 1, followed by 500 mg every 24 hours (Tanoue 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis (PD): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CVVHD: 1,000 mg every 8 hours (Vossen 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CVVHDF: 250 mg every 12 hours (Hidaka 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15804872\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied); however, doripenem undergoes minimal hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432449\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doribax: 250 mg (1 ea [DSC]); 500 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg (1 ea); 500 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432404\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432444\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 1 hour.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432408\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections, complicated: </b>Treatment of complicated intra-abdominal infections caused by <i>Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Escherichia coli, Klebsiella pneumoniae, Peptostreptococcus micros, Pseudomonas aeruginosa, Streptococcus intermedius, </i>and <i>Streptococcus constellatus</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections, complicated (including pyelonephritis):</b> Treatment of complicated urinary tract infections (UTIs), including pyelonephritis, caused by <i>E. coli</i> (including cases with concurrent bacteremia), <i>Acinetobacter baumannii, K. pneumoniae, Proteus mirabilis,</i> and <i>P. aeruginosa</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725323\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Catheter-related bloodstream infections (adults); Osteomyelitis, native vertebral</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10907726\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doripenem may be confused with ertapenem</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Doribax may be confused with Zovirax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432418\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (6% to 12%), nausea (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Phlebitis (2% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1% to 6%; includes allergic/bullous dermatitis, erythema, macular/papular eruptions, urticaria, and erythema multiforme), pruritus (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral candidiasis (1% to 3%), <i>Clostridium difficile</i> associated diarrhea (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal infection (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (2% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (2% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, interstitial pneumonitis, leukopenia, neutropenia, renal failure, renal insufficiency, seizure, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432414\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known serious hypersensitivity to doripenem, any component of the formulation or other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432415\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, and skin reactions have been reported in patients receiving beta-lactams.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states; seizures with doripenem have been reported. Use caution with CNS disorders (eg, brain lesions, stroke, or history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. Patients receiving doses &gt;500 mg every 8 hours may also be at increased risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate-to-severe renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ventilator-associated pneumonia: Not approved for the treatment of pneumonia including hospital-associated pneumonia (HAP) and ventilator-associated pneumonia (VAP). Demonstrated numerically lower cure rate (versus a comparator antibiotic) and increased mortality rate in patients with VAP in a Phase 3 study using a higher dose and fixed 7-day administration (Kollef 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Administer via intravenous infusion only. Per manufacturer&rsquo;s labeling, investigational experience of doripenem via inhalation resulted in pneumonitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299228\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432425\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9358&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432410\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432411\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Information related to use during pregnancy has not been located.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6189124\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if doripenem is excreted into breast milk. The manufacturer recommends that caution be exercised when administering doripenem to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432447\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs of anaphylaxis during first dose; periodic renal assessment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432431\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to several of the penicillin-binding proteins (PBP-2, PBP-3, PBP-4), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis; bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432433\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Penetrates well into body fluids and tissues, including peritoneal and retroperitoneal fluids, gallbladder, bile, and urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: 16.8 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~8.1%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Non-CYP-mediated metabolism via hydrolysis by dehydropeptidase-I to doripenem-M1 (inactive metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (71% as unchanged drug; 15% as doripenem-M1 metabolite); feces (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321785\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Doripenem Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $24.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $45.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961932\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Daryaven (ID);</li>\n      <li>Doribaks (UA);</li>\n      <li>Doribax (AR, AT, CO, CY, CZ, DE, EE, FR, GR, HK, HR, HU, ID, IL, JO, KW, LB, MT, MY, NL, PH, PL, QA, SA, SE, SG, SI, TH, TR, VN);</li>\n      <li>Doriglen (IN);</li>\n      <li>Dorinem IV (BD);</li>\n      <li>Doripen (BD);</li>\n      <li>Doriprex (RU);</li>\n      <li>Durapta (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Finibax (JP, KR, TW);</li>\n      <li>Icupen (IN);</li>\n      <li>Perinem (BD);</li>\n      <li>Savador (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span><span class=\"doi\">10.1093/cid/civ482</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doribax (doripenem) [prescribing information]. Florham Park, NJ: Shionogi Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hidaka S, Goto K, Hagiwara S, et al, &ldquo;Doripenem Pharmacokinetics in Critically Ill Patients Receiving Continuous Hemodiafiltration (CHDF,&rdquo; <i>Yakugaku Zasshi</i> [in English], 2010, 130(1):87-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/20046071/pubmed\" target=\"_blank\" id=\"20046071\">20046071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jenkins SG, Fisher AC, Peterson JA, et al, &ldquo;Meta-analysis of Doripenem vs Comparators in Patients with Pseudomonas Infections Enrolled in Four Phase III Efficacy and Safety Trials,&rdquo; <i>Curr Med Res Opin</i>, 2009, 25(12):3029-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/19849650/pubmed\" target=\"_blank\" id=\"19849650\">19849650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keam SJ, &ldquo;Doripenem: A Review of Its Use in the Treatment of Bacterial Infections,&rdquo; <i>Drugs</i>, 2008, 68(14):2021-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/18778123/pubmed\" target=\"_blank\" id=\"18778123\">18778123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kollef MH, Chastre J, Clavel M, et al, &ldquo;A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia,&rdquo; <i>Crit Care</i>, 2012, 16(6):R218. [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/23148736/pubmed\" target=\"_blank\" id=\"23148736\">23148736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kollef MH, Nathwani D, Merchant S, et al, &ldquo;Medical Resource Utilization Among Patients With Ventilator-Associated Pneumonia: Pooled Analysis of Randomized Studies of Doripenem versus Comparators,&rdquo; <i>Crit Care</i>, 2010, 14(3):R84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/20459721/pubmed\" target=\"_blank\" id=\"20459721\">20459721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lo TS, Borchardt SM, Welch JM, et al, &ldquo;Doripenem in Hospital Infections: A Focus on Nosocomial Pneumonia, Complicated Intra-Abdominal Infections, and Complicated Urinary Tract Infections,&rdquo; <i>Infect Drug Resist</i>, 2009, 2:41-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/21694886/pubmed\" target=\"_blank\" id=\"21694886\">21694886</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al, &ldquo;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2009, 49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parkins MD and Elborn JS, &ldquo;Newer Antimicrobial Agents and Their Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management,&rdquo; <i>J Antimicrob Chemother</i>, 2010, 65(9):1853-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/20605846/pubmed\" target=\"_blank\" id=\"20605846\">20605846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    R&eacute;a-Neto A, Niederman M, Lobo SM, et al, &ldquo;Efficacy and Safety of Doripenem versus Piperacillin/Tazobactam in Nosocomial Pneumonia: A Randomized, Open-label, Multicenter Study,&rdquo; <i>Curr Med Res Opin</i>, 2008, 24(7):2113-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/18549664/pubmed\" target=\"_blank\" id=\"18549664\">18549664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>,  2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanoue K, Nishi K, Kadowaki D, et al, &ldquo;Removal of Doripenem During Hemodialysis and the Optimum Dosing Regimen for Patients Undergoing Hemodialysis,&rdquo; <i>Ther Apher Dial</i>, 2011, 15(3):327-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/21624085/pubmed\" target=\"_blank\" id=\"21624085\">21624085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, <i>Handbook on Injectable Drugs</i>, 16th ed, American Society of Health-System Pharmacists&reg;, Bethesda, MD: 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26711775\"></a>Vossen MG, Wenisch JM, Maier-Salamon A, et al. Doripenem treatment during continuous renal replacement therapy. <i>Antimicrob Agents Chemother</i>. 2015;60(3):1687-1694. doi: 10.1128/AAC.01801-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/26711775/pubmed\" target=\"_blank\" id=\"26711775\">26711775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhanel GG, Wiebe R, Dilay L, et al, &ldquo;Comparative Review of the Carbapenems,&rdquo; <i>Drugs</i>, 2007, 67(7):1027-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doripenem-drug-information/abstract-text/17488146/pubmed\" target=\"_blank\" id=\"17488146\">17488146</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9358 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10805264\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5432406\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5432441\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5432442\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5432443\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15804872\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5432449\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5432404\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5432444\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5432408\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725323\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10907726\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5432418\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5432414\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5432415\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299228\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5432425\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F5432410\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5432411\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6189124\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5432447\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5432431\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5432433\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321785\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961932\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9358|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=doripenem-patient-drug-information\" class=\"drug drug_patient\">Doripenem: Patient drug information</a></li></ul></div></div>","javascript":null}